BD Injects €3.5m into Irish Facility
The €3.5m has been invested into new equipment to manufacture insulin pen needles, lancet blood sampling devices and BD’s Posiflush syringes - a prefilled saline and heparin lock flush hypodermic - at Becton, Dickinson and Company's (BD) facility in Drogheda, County Louth.
“This investment in Drogheda is part of the Company’s investment strategy for Ireland, which has also seen more than €34 million invested in our other plant in Dun Laoghaire, Co Dublin,” said Cormac Reynolds, Director of Diabetes Care Manufacturing for BD in Ireland.
CEO of the Industrial Development Authority (IDA) Ireland, Barry O’Leary, welcomed the news, adding: “Continuous innovation by companies is vital in order to stay competitive – what BD has done here in Drogheda is a prime example of this.”
